Freeline Therapeutics Holdings is a clinical-stage, systemic adeno-associated virus-based gene therapy company. Co.'s pipeline includes programs in the clinic and late-stage preclinical product candidates, as well as research programs targeting applications for systemic gene therapy. Co.'s product candidate, verbrinacogene setparvovec (FLT180a) is intended for the treatment of patients in whom a deficiency of functional clotting Factor IX, causes moderate or severe hemophilia B. Co. is also developing FLT190 for the treatment of Fabry disease, as well as FLT201 and FLT210, for the treatment of Gaucher disease and hemophilia A, respectively. We show 1 historical shares outstanding datapoints in our coverage of FRLN's shares outstanding history.
Understanding the changing numbers of FRLN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like FRLN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching FRLN by allowing them to research FRLN shares outstanding history
as well as any other stock in our coverage universe. |
Free FRLN Email Alerts:
Video: Shares Outstanding Importance
